Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
542
Recruiting Now
542
Top Conditions in Phase 3
Frequently Asked Questions — Phase 3 Trials
Why are Phase 3 trials the standard for drug approval?
Phase 3 trials compare a new treatment against the current standard of care in a large, randomized population of 300–3,000+ participants. This large-scale comparative evidence is what regulatory agencies—FDA, EMA—require to approve a new drug. A successful Phase 3 trial demonstrates that the new treatment is more effective, safer, or both compared to existing options in a statistically significant, reproducible way.
What is a placebo control in a Phase 3 trial?
Many Phase 3 trials use a placebo control—a group that receives an inactive substance—to isolate the true effect of the treatment. When an established standard of care exists, control-arm participants typically receive that treatment rather than a placebo, for ethical reasons. Blinded designs prevent participants and investigators from knowing who received which treatment, reducing bias in outcome assessment.
How do I find and join a Phase 3 clinical trial?
ClinicalMetric lists all Phase 3 trials registered on ClinicalTrials.gov. Each trial card shows recruitment status, enrollment target, sponsor, conditions studied, and site locations. To join a Phase 3 trial, review the eligibility criteria and contact the trial site directly—usually an academic medical center or hospital. Your physician can facilitate a referral to the appropriate study site.
Active Phase 3 Studies
NCT07495852 Phase 3
Recruiting
Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost In...
Condition
Glaucoma
Enrollment
510 pts
Location
United States
Sponsor
Glaukos Corporation
NCT06079918 Phase 3
Recruiting
Multiple Micronutrient Supplementation for Maternal Anemia Prevention in Tanzani...
Condition
Pregnancy Related
Enrollment
6,381 pts
Location
Tanzania
Sponsor
George Washington University
NCT06651697 Phase 3
Recruiting
BladdEr Full OR Empty for Pelvic Radiation Therapy
Condition
Pelvic Neoplasm
Enrollment
300 pts
Location
United States
Sponsor
University of California, San
NCT04217733 Phase 3
Recruiting
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Ir...
Condition
IBS - Irritable Bowel Syndrome
Enrollment
60 pts
Location
Egypt
Sponsor
Tanta University
NCT07016126 Phase 3
Recruiting
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA o...
Condition
NSCLC (Non-small Cell Lung Cancer)
Enrollment
70 pts
Location
China
Sponsor
Guangdong Provincial People's
NCT07361510 Phase 3
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participan...
Condition
Non-Small Cell Lung Cancer (NSCLC)
Enrollment
750 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06929624 Phase 3
Recruiting
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Di...
Condition
Diffuse Large B-cell Lymphoma
Enrollment
280 pts
Location
China
Sponsor
Suzhou Suncadia Biopharmaceuti
NCT05999630 Phase 3
Recruiting
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated Wi...
Condition
Nasolacrimal Duct Obstruction
Enrollment
100 pts
Location
United States
Sponsor
Vanderbilt University Medical
NCT06026878 Phase 3
Recruiting
GNT Induction Treatment in Locally Advanced NPC
Condition
Nasopharyngeal Carcinoma
Enrollment
228 pts
Location
China
Sponsor
Air Force Military Medical Uni
NCT06065449 Phase 3
Recruiting
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT...
Condition
Bone Metastases
Enrollment
220 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT07333274 Phase 3
Recruiting
Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-inel...
Condition
Head & Neck Squamous Cell Carcinoma
Enrollment
335 pts
Location
China
Sponsor
Shandong Cancer Hospital and I
NCT06617325 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Part...
Condition
Systemic Lupus Erythematosus
Enrollment
450 pts
Location
United States, Argentina, Belgium
Sponsor
UCB Biopharma SRL
NCT07052903 Phase 3
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloid...
Condition
Transthyretin Amyloidosis With Cardiomyopathy
Enrollment
1,750 pts
Location
United States, Argentina, Australia
Sponsor
Alnylam Pharmaceuticals
NCT06174753 Phase 3
Recruiting
Dapagliflozin in STEMI
Condition
ST Elevation Myocardial Infarction
Enrollment
256 pts
Location
Canada
Sponsor
Ottawa Heart Institute Researc
NCT07327619 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HAB...
Condition
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Enrollment
420 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
NCT06708741 Phase 3
Recruiting
Regime for Vitamin D Maintenance in Post-Operative Patients
Condition
Sarcopenia
Enrollment
100 pts
Location
Singapore
Sponsor
Sengkang General Hospital
NCT04168502 Phase 3
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AM...
Condition
Acute Myeloid Leukemia
Enrollment
414 pts
Location
Italy
Sponsor
Gruppo Italiano Malattie EMato
NCT07299695 Phase 3
Recruiting
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathi...
Condition
Idiopathic Pulmonary Fibrosis
Enrollment
196 pts
Location
Greece
Sponsor
Argyrios Tzouvelekis
NCT06875973 Phase 3
Recruiting
Pelacarsen Roll-over Extension Program
Condition
Atherosclerotic Cardiovascular Disease
Enrollment
599 pts
Location
United States, Puerto Rico
Sponsor
Novartis Pharmaceuticals
NCT07080229 Phase 3
Recruiting
Intranasal Dexmedetomidine on Blood Pressure in Elderly Hypertensive Patients Un...
Condition
Cataract
Enrollment
126 pts
Location
Egypt
Sponsor
Suez Canal University
NCT05834777 Phase 3
Recruiting
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Condition
Intradialytic Hypotension
Enrollment
26 pts
Location
United States
Sponsor
Vanderbilt University Medical
NCT06072781 Phase 3
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade ...
Condition
Low Grade Serous Ovarian Cancer
Enrollment
270 pts
Location
United States, Australia, Belgium
Sponsor
Verastem, Inc.
NCT06971094 Phase 3
Recruiting
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Inject...
Condition
SMA - Spinal Muscular Atrophy
Enrollment
50 pts
Location
China
Sponsor
GeneCradle Inc
NCT06387069 Phase 3
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid ...
Condition
Acute Myeloid Leukemia
Enrollment
316 pts
Location
China
Sponsor
Hutchmed
NCT06247605 Phase 3
Recruiting
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
Condition
Small Cell Lung Carcinoma
Enrollment
243 pts
Location
China
Sponsor
Advenchen Laboratories Nanjing
Page 1 of 22 — 542 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology